Skip to main content
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: Gynecol Oncol. 2009 Nov 28;116(3):378. doi: 10.1016/j.ygyno.2009.10.087

Table 3.

Sensitivity of the screening tests by risk status and ovarian cancer stage.

Sensitivity by Risk Status* Sensitivity by Ovarian Cancer Stage*
Screening Tests+ Number of Average
Risk Cases with
Positive Screening
Test
(n=60)		 Sensitivity in
Average Risk
Cases		 Number of
High Risk Cases
with Positive
Screening Test
(n=14)		 Sensitivity in
High Risk Cases		 Number of
Early Stage Cases
with Positive
Screening Test
(n=31)		 Sensitivity in
Early Stage Cases		 Number of
Late Stage Cases
with Positive
Screening Test
(n=41)		 Sensitivity in
Late Stage Cases
CA125 49 81.7 (69.6 – 90.5) 11 78.6 (49.2–95.3) 21 67.7 (48.6 – 83.3) 38 92.7 (80.1 – 98.5)
HE4 43 71.7 (58.6 – 82.5) 14 100 (76.8–100) 18 58.1 (39.1 – 75.5) 38 92.7 (80.1 – 98.5)
Symptom Index
(SI) 		38 63.3 (49.9–75.4) 9 64.3 (35.1–87.2) 14 45.2 (27.3–64.0) 32 78.0 (62.4–89.4)
CA125 or HE4 52 86.7 (75.4 – 94.1) 14 100 (76.8–100) 25 80.6 (62.5 – 92.5) 40 97.6 (87.1 – 99.9)
SI or CA125 54 90.0 (79.5 – 96.2) 14 100 (76.8–100) 26 83.9 (66.3 – 94.5) 40 97.6 (87.1 – 99.9)
SI or HE4 54 90.0 (79.5 – 96.2) 14 100 (76.8–100) 26 83.9 (66.3 – 94.5) 40 97.6 (87.1 – 99.9)
Any 1 of 3 tests
positive 		56 93.3 (83.8 – 98.2) 14 100 (76.8–100) 28 90.3 (74.2 – 98.0) 40 97.6 (87.1 – 99.9)
Any 2 of 3 tests
positive 		48 80.0 (67.7–89.2) 14 100 (76.8–100) 21 67.7 (48.6–83.3) 40 97.6 (87.1 – 99.9)
SI and at least 1
additional test
positive 		34 56.7 (43.2 – 69.4) 9 64.3 (35.1–87.2) 11 35.5 (19.2–54.6) 32 78.0 (62.4–89.4)
*

Sensitivity = true positives/ (true positives + false negatives)

+

See Table 1 for descriptions of the screening tests and biomarker combinations.